Monitoring metabolic side effects of atypical antipsychotics in people with an intellectual disability

Journal of Intellectual Disabilities

Volumn 17, Issue 3, 2013, Pages 223-235

  Teeluckdharry, Sadira ^a   Sharma, Sujit ^b   O'Rourke, Elizabeth ^b   Tharian, Priyanka ^a   Gondalekar, Anjali ^c   Nainar, Feroz ^d   Roy, Meera ^e  

^a BIRMINGHAM AND SOLIHULL MENTAL HEALTH NHS FOUNDATION TRUST   (United Kingdom)

^b West Midlands Deanery ^*  (United Kingdom)

^c WORCESTERSHIRE ACUTE HOSPITALS NHS TRUST   (United Kingdom)

^d Birmingham Community Healthcare NHS Trust ^*  (United Kingdom)

^e Jaffray Resource Centre   (United Kingdom)

Author keywords

Atypical antipsychotics; Intellectual disability; Metabolic syndrome; Monitoring

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; GLUCOSE; LIPID; OLANZAPINE; QUETIAPINE; RISPERIDONE;

ARTICLE; BLOOD PRESSURE MONITORING; BODY MASS; CARDIOVASCULAR RISK; DRUG SURVEILLANCE PROGRAM; FAMILY HISTORY; GLUCOSE BLOOD LEVEL; HUMAN; INTELLECTUAL IMPAIRMENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; SCHIZOPHRENIA; WAIST CIRCUMFERENCE;

ATYPICAL ANTIPSYCHOTICS; INTELLECTUAL DISABILITY; METABOLIC SYNDROME; MONITORING;

ADULT; ANTIPSYCHOTIC AGENTS; DRUG MONITORING; GUIDELINES AS TOPIC; HUMANS; INTELLECTUAL DISABILITY; MEDICAL AUDIT; METABOLIC SYNDROME X; PSYCHIATRY;

EID: 84884833516     PISSN: 17446295     EISSN: 17446309     Source Type: Journal    
DOI: 10.1177/1744629513495261     Document Type: Article

References (31)

1. Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC, et al. (1999) Antipsychotic-induced weight gain: a comprehensive research synthesis. American Journal of Psychiatry 156(11): 1686-1696. (Pubitemid 29517559)
2. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists and North American Association for the Study of Obesity (2004) Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes. Diabetes Care 27(2): 596-601.
3. Baburaj R and El Tahir M (2011) Monitoring for metabolic syndrome in people with intellectual disability on antipsychotic medication. Advances in Mental Health and Intellectual Disabilities 5(3): 38-44.
4. Bhaumik S, Watson JM, Thorp CF, Tryrer F and McGrother CW (2008) BMI in adults with intellectual disability, distribution, association and service implications: a population based prevalence study. Journal of Intellectual Disability Research 52(4): 287-298. (Pubitemid 351404267)
5. Clarke DJ, Kelley S, Thinn K and Corbett JA (1990) Psychotropic drugs and mental retardation: 1. Disabilities and the prescription of drugs for behaviour and for epilepsy in 3 residential settings. J Ment Defic Res 28: 229-233.
6. Cohn TA and Sernyak MJ (2006) Metabolic monitoring for patients treated with antipsychotic medications. Can J Psychiatry 51(8): 492-501. (Pubitemid 44166337)
7. Deb S and Fraser W (1994) The use of medication in people with learning disability: towards more rational prescribing. Hum Psychopharmacol 9: 259-272. (Pubitemid 24277706)
8. Deb S, Kwok H, Bertelli M, Salvador Carulla L, Bradley E, Torr J, et al. (2009) International guide to prescribing psychotropic medication for the management of problem behaviours in adults with intellectual disabilities. World Psychiatry 8: 181-186.
9. Devapriam JA, Anand A, Raju LB and Bhaumik S (2009) Monitoring for metabolic syndrome in adults with intellectual disability on atypical antipsychotic drugs. British Journal of Developmental Disabilities 55(108) Pt1: 3-13.
10. de Winter CF, Magilsen KW, van Alfen JC, Willemsen SP and Evenhuis HM (2011) Metabolic syndrome in 25% of older people with intellectual disability. Family Practice 28(2): 141-144.
11. Dixon L, Weiden P, Delahanty J, Goldberg R, Postrado L, Lucksted A, et al. (2000) Prevalence and correlates of diabetes in national schizophrenia samples. Schizophrenia Bulletin 26(4): 903-912.
12. Flaum M (2010) Strategies to close the mortality gap. American Journal of Psychiatry 167(2): 120-121.
13. Hasnain M, Vieweg WV, Fredrickson SK, Beatty-Brooks M, Fernandez A and Pandurangi AK (2009) Clinical monitoring and management of the metabolic syndrome in patients receiving atypical antipsychotic medications. Primary Care Diabetes 3: 5-15.
14. Heald A (2010) Physical health in schizophrenia: a challenge for antipsychotic therapy. European Psychiatry 25: S6-S11.
15. Hollins S, Attard M, van Fraunhofer N, McGuigan SM and Sedgwick P (1998) Mortality in people with learning disability: risks causes, and death certification findings in London. Developmental Medicine and Child Neurology 40: 50-56. (Pubitemid 28036991)
16. Kane JM and Correll CU (2010) Past and present progress in the pharmacologic treatment of Schizophrenia. Journal of Clinical Psychiatry 71(9): 1115-1124.
17. Lean MEJ and Pajonk FG.(2003) Patients on atypical antipsychotic drugs. Diabetes Care 26(5): 1597-1605.
18. Mackin P, Bishop DR and Watkinson HM (2007) A prospective study of monitoring practices for metabolic disease in antipsychotic-treated community psychiatric patients. BMC Psychiatry 7: 28, 1-6.
19. Marder SR, Essock SM, Miller AL, Buchanan RW, Casey DE, Davis JM, et al. (2004) Physical health monitoring of patients with schizophrenia. American Journal of Psychiatry 161(8): 1334-1349. (Pubitemid 38989085)
20. McCrae J (2010) Physical health concerns of the patient, the family and the carer. European Psychiatry 25; S34-S36.
21. Millar HL (2010) Development of a health screening clinic. European Psychiatry 25: S29-S33.
22. Montejo A (2010) The need for routine physical health care in schizophrenia. European Psychiatry 25: S3-S5.
23. Morrato EH, Nicol GE, Maahs D, Druss BG, Hartung DM, Valuck RJ, et al. (2010) Metabolic screening in children receiving antipsychotic drug treatment. Archives of Pediatrics and Adolescent Medicine 164(4): 344-351.
24. Nasrallah HA (2006) Metabolic findings from the CATIE trial and their relation to tolerability. CNS Spectrums 11(7 Suppl 7): 32-39. (Pubitemid 44141227)
25. National Clinical Guideline (NICE) (2010) National Clinical Guideline No:82. Schizophrenia: core interventions in the treatment and management of schizophrenia in primary and secondary care (updated edition). London: British Psychological Society and Royal College of Psychiatrists.
26. Newcomer JW (2007) Metabolic syndrome and mental illness. American Journal of Managed Care 13: S170-S177. (Pubitemid 350231678)
27. Pramyothin P and Khaodhiar L (2010) Metabolic syndrome with the atypical antipsychotics. Current Opinion in Endocrinology, Diabetes and Obesity 17: 460-466.
28. Roy A, Jain S, Roy A, Ward F, Richings C, Martin M, et al. (2011) Improving recording of capacity and explanation of medication side effects in a psychiatric service for people with learning disability: audit findings. Journal of Intellectual Disability 15(2): 85-92.
29. Spreat S, Conroy J and Jones J (1997) Use of psychotropic medication in Oklahoma: a statewide survey. American Journal on Mental Retardation 102: 80-85. (Pubitemid 27334712)
30. Stahl SM, Mignon L and Meyer JM (2009) Which comes first: atypical antipsychotic treatment or cardiometabolic risk? Acta Psychiatrica Scandinavica 119: 171-179.
31. Toalson P, Ahmed S, Hardy T and Kabinoff G (2004) The metabolic syndrome in patients with severe mental illnesses. The Primary Care Companion to the Journal of Clinical Psychiatry 6: 152-158.